Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Alger Weatherbie Specialized Growth Fund 2024 Q2 Investor Letter | Buyside Digest

Back to Fund Profile (Alger Weatherbie Specialized Growth Fund)

Primary Source Intelligence • Q2 2024 Letter Analysis

Alger Weatherbie Specialized Growth Fund Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Alger Weatherbie Specialized Growth Fund. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

Annualized+8.15%

Digest Analysis

Quick Take

"Small-cap growth fund focusing on secular themes including AI, cloud computing, and healthcare innovation. Outperformed benchmark in Q2 despite negative returns, driven by strong performance from genetic testing company Natera and glaucoma device maker Glaukos."

Executive Summary

The Alger Weatherbie Specialized Growth Fund focuses on approximately 50 small and mid-cap companies with promising growth potential, seeking long-term capital appreciation. During Q2 2024, the fund underperformed with a -0.24% return versus the Russell 2500 Growth Index's -4.22% decline, benefiting from overweights in Health Care and underweights in Consumer Discretionary. Top contributors included StepStone Group, which beat earnings estimates with strong fundraising activity, Natera, which reported strong genetic testing results and raised guidance, and Glaukos, whose innovative iDose glaucoma technology showed growing physician adoption. Detractors included SiteOne Landscape Supply, which faced margin pressures, Progyny, affected by macroeconomic uncertainty in fertility markets, and Sprout Social, which reduced guidance due to enterprise software spending slowdowns. The managers continue to focus on secular themes including AI at an inflection point, cloud computing growth supporting corporate digitization, and healthcare innovations in genomic sequencing and surgical technologies as key investment opportunities.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

The fund demonstrates moderate-high conviction through its focused portfolio of approximately 50 holdings with clear thematic positioning. Individual holdings are well-researched with detailed thesis explanations, and the manager expresses strong views on specific companies like Glaukos's transformational iDose technology. However, the diversified nature of 50 holdings prevents a higher conviction score.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The manager expresses cautious optimism about markets, noting positive developments like growing confidence in a soft landing and easing inflation pressures, but also acknowledges challenges including adjusted Fed rate expectations and macroeconomic uncertainty affecting enterprise spending.

Risk Appetite

40%

DefensiveAggressive

Defensive (40%)

The fund maintains a focused portfolio of approximately 50 holdings with meaningful sector overweights in Health Care, suggesting moderate risk appetite. The positioning reflects selective risk-taking in growth themes while maintaining diversification across sectors.

Capital Deployment

0%

De-riskingDeploying

De-risking (0%)

No specific information provided about cash level changes or net deployment activity during the quarter. The letter focuses on existing portfolio performance and positioning without indicating material changes in capital deployment.

Forward Guidance

30%

CautiousExpansionary

Cautious (30%)

The manager indicates continued focus on secular themes and investment opportunities but does not express strong deployment intentions. The tone suggests selective monitoring of opportunities rather than aggressive capital deployment.

Language Signal

20%

BearishBullish

Bearish (20%)

Language is balanced with both opportunity-focused terms like 'attractive investment opportunities' and 'compelling opportunities' alongside risk acknowledgments including 'uncertain macroeconomic environment' and 'margin pressures.' Slightly more cautious than bullish overall.

Perceived Risk

45%

Low RiskElevated

Moderate Risk (45%)

The manager acknowledges moderate risks including adjusted Fed expectations, macroeconomic uncertainty affecting enterprise software spending, and sector-specific challenges like fertility market disruptions. Risks are mentioned but not characterized as systemic or severe.

Opportunity Density

65%

ScarceAbundant

Abundant (65%)

The manager identifies multiple secular themes creating attractive investment opportunities including AI, cloud computing, corporate digitization, and healthcare innovations. The tone suggests a reasonably rich opportunity set across these defined thematic areas, though selectivity is required.

Time Horizon

70%

Short-TermLong-Term

Decade+ (70%)

The fund explicitly seeks long-term capital appreciation and focuses on secular themes expected to play out over multiple years. The manager discusses transformational technologies like iDose and multi-year trends in AI and cloud computing, indicating a patient, multi-year investment horizon.